Search Results for: Influenza

1761 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
AR and GTF2F1 androgen receptor general transcription factor IIF, polypeptide 1, 74kDa
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • RNA Polymerase II Promoter Escape
  • mRNA Splicing
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase II Transcription
  • Abortive elongation of HIV-1 transcript in the absence of Tat
  • HIV Infection
  • Formation of the Early Elongation Complex
  • Tat-mediated elongation of the HIV-1 transcript
  • Tat-mediated HIV elongation arrest and recovery
  • RNA Pol II CTD phosphorylation and interaction with CE
  • RNA Polymerase II Pre-transcription Events
  • Influenza Life Cycle
  • HIV elongation arrest and recovery
  • HIV Transcription Initiation
  • HIV Life Cycle
  • RNA Pol II CTD phosphorylation and interaction with CE
  • Influenza Viral RNA Transcription and Replication
  • RNA Polymerase II HIV Promoter Escape
  • HIV Transcription Elongation
  • Processing of Capped Intron-Containing Pre-mRNA
  • mRNA Capping
  • mRNA Splicing - Minor Pathway
  • mRNA Splicing - Major Pathway
  • Influenza Infection
  • Pausing and recovery of Tat-mediated HIV elongation
  • Late Phase of HIV Life Cycle
  • Formation of RNA Pol II elongation complex
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • Pausing and recovery of HIV elongation
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Formation of the HIV-1 Early Elongation Complex
  • Viral Messenger RNA Synthesis
  • RNA Polymerase II Transcription Initiation
  • Transcription of the HIV genome
  • RNA Polymerase II Transcription Elongation
  • Levonorgestrel
  • Spironolactone
  • Flutamide
  • Oxandrolone
  • Testosterone
  • Nilutamide
  • Fludrocortisone
  • Drostanolone
  • Nandrolone phenpropionate
  • Bicalutamide
  • Fluoxymesterone
  • Drospirenone
  • Danazol
  • Testosterone Propionate
  • Delta1-dihydrotestosterone
  • Boldenone
  • Calusterone
  • Flufenamic Acid
  • Dihydrotestosterone
  • (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
  • Methyltrienolone
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
  • Cyproterone
  • Methyltestosterone
  • 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  • 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
  • (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
  • 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
  • (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
  • 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
  • Nandrolone decanoate
  • Enzalutamide
AR and GTF2F2 androgen receptor general transcription factor IIF, polypeptide 2, 30kDa
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • RNA Polymerase II Promoter Escape
  • mRNA Splicing
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase II Transcription
  • Abortive elongation of HIV-1 transcript in the absence of Tat
  • HIV Infection
  • Formation of the Early Elongation Complex
  • Tat-mediated elongation of the HIV-1 transcript
  • Tat-mediated HIV elongation arrest and recovery
  • RNA Pol II CTD phosphorylation and interaction with CE
  • RNA Polymerase II Pre-transcription Events
  • Influenza Life Cycle
  • HIV elongation arrest and recovery
  • HIV Transcription Initiation
  • HIV Life Cycle
  • RNA Pol II CTD phosphorylation and interaction with CE
  • Influenza Viral RNA Transcription and Replication
  • RNA Polymerase II HIV Promoter Escape
  • HIV Transcription Elongation
  • Processing of Capped Intron-Containing Pre-mRNA
  • mRNA Capping
  • mRNA Splicing - Minor Pathway
  • mRNA Splicing - Major Pathway
  • Influenza Infection
  • Pausing and recovery of Tat-mediated HIV elongation
  • Late Phase of HIV Life Cycle
  • Formation of RNA Pol II elongation complex
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • Pausing and recovery of HIV elongation
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Formation of the HIV-1 Early Elongation Complex
  • Viral Messenger RNA Synthesis
  • RNA Polymerase II Transcription Initiation
  • Transcription of the HIV genome
  • RNA Polymerase II Transcription Elongation
  • Levonorgestrel
  • Spironolactone
  • Flutamide
  • Oxandrolone
  • Testosterone
  • Nilutamide
  • Fludrocortisone
  • Drostanolone
  • Nandrolone phenpropionate
  • Bicalutamide
  • Fluoxymesterone
  • Drospirenone
  • Danazol
  • Testosterone Propionate
  • Delta1-dihydrotestosterone
  • Boldenone
  • Calusterone
  • Flufenamic Acid
  • Dihydrotestosterone
  • (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
  • Methyltrienolone
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
  • Cyproterone
  • Methyltestosterone
  • 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  • 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
  • (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
  • 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
  • (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
  • 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
  • Nandrolone decanoate
  • Enzalutamide
NR3C1 and CALR nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) calreticulin
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Diseases of glycosylation
  • Defective ALG14 causes congenital myasthenic syndrome (ALG14-CMS)
  • Defective MGAT2 causes MGAT2-CDG (CDG-2a)
  • Defective ALG1 causes ALG1-CDG (CDG-1k)
  • Antigen Presentation: Folding, assembly and peptide loading of class I MHC
  • Virus Assembly and Release
  • Defective MOGS causes MOGS-CDG (CDG-2b)
  • Influenza Life Cycle
  • Defective ALG9 causes ALG9-CDG (CDG-1l)
  • Defective MAN1B1 causes MRT15
  • Scavenging by Class F Receptors
  • Class I MHC mediated antigen processing & presentation
  • N-glycan trimming in the ER and Calnexin/Calreticulin cycle
  • Scavenging by Class A Receptors
  • Assembly of Viral Components at the Budding Site
  • ATF6-alpha activates chaperones
  • Unfolded Protein Response (UPR)
  • Defective ALG11 causes ALG11-CDG (CDG-1p)
  • Defective ALG2 causes ALG2-CDG (CDG-1i)
  • Post-translational protein modification
  • Defective ALG3 causes ALG3-CDG (CDG-1d)
  • Defective DPAGT1 causes DPAGT1-CDG (CDG-1j) and CMSTA2
  • Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)
  • ATF6-alpha activates chaperone genes
  • Influenza Infection
  • Defective RFT1 causes RFT1-CDG (CDG-1n)
  • Defective ALG6 causes ALG6-CDG (CDG-1c)
  • Asparagine N-linked glycosylation
  • Defective ALG8 causes ALG8-CDG (CDG-1h)
  • Defective MPDU1 causes MPDU1-CDG (CDG-1f)
  • Defective ALG12 causes ALG12-CDG (CDG-1g)
  • Antigen processing-Cross presentation
  • ER-Phagosome pathway
  • Diseases associated with N-glycosylation of proteins
  • Adaptive Immune System
  • Calnexin/calreticulin cycle
  • Flunisolide
  • Diflorasone
  • Alclometasone
  • Medrysone
  • Amcinonide
  • Fluorometholone
  • Megestrol
  • Beclometasone dipropionate
  • Betamethasone
  • Desoximetasone
  • Fluticasone Propionate
  • Fluocinolone Acetonide
  • Halobetasol Propionate
  • Triamcinolone
  • Prednisone
  • Flumethasone Pivalate
  • Fludrocortisone
  • Hydrocortisone
  • Mometasone
  • Hydrocortamate
  • Mifepristone
  • Clocortolone
  • Flurandrenolide
  • Prednisolone
  • Loteprednol
  • Rimexolone
  • Methylprednisolone
  • Clobetasol
  • Fluocinonide
  • Prednicarbate
  • Fluoxymesterone
  • Budesonide
  • Dexamethasone
  • Desonide
  • Cortisone acetate
  • Paramethasone
  • Ciclesonide
  • Hexane-1,6-Diol
  • Difluprednate
  • Fluticasone furoate
NR3C1 and HSPA1A nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) heat shock 70kDa protein 1A
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Regulation of mRNA stability by proteins that bind AU-rich elements
  • Viral RNP Complexes in the Host Cell Nucleus
  • Attenuation phase
  • Regulation of HSF1-mediated heat shock response
  • Cellular response to heat stress
  • AUF1 (hnRNP D0) destabilizes mRNA
  • Influenza Infection
  • Influenza Life Cycle
  • HSF1-dependent transactivation
  • Export of Viral Ribonucleoproteins from Nucleus
  • Flunisolide
  • Diflorasone
  • Alclometasone
  • Medrysone
  • Amcinonide
  • Fluorometholone
  • Megestrol
  • Beclometasone dipropionate
  • Betamethasone
  • Desoximetasone
  • Fluticasone Propionate
  • Fluocinolone Acetonide
  • Halobetasol Propionate
  • Triamcinolone
  • Prednisone
  • Flumethasone Pivalate
  • Fludrocortisone
  • Hydrocortisone
  • Mometasone
  • Hydrocortamate
  • Mifepristone
  • Clocortolone
  • Flurandrenolide
  • Prednisolone
  • Loteprednol
  • Rimexolone
  • Methylprednisolone
  • Clobetasol
  • Fluocinonide
  • Prednicarbate
  • Fluoxymesterone
  • Budesonide
  • Dexamethasone
  • Desonide
  • Cortisone acetate
  • Paramethasone
  • Ciclesonide
  • Hexane-1,6-Diol
  • Difluprednate
  • Fluticasone furoate
NR3C1 and RAN nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) RAN, member RAS oncogene family
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Transcriptional regulation by small RNAs
  • Metabolism of lipids and lipoproteins
  • Nuclear import of Rev protein
  • HIV Infection
  • Regulatory RNA pathways
  • Rev-mediated nuclear export of HIV RNA
  • Host Interactions of HIV factors
  • MicroRNA (miRNA) biogenesis
  • Influenza Infection
  • Interactions of Rev with host cellular proteins
  • Late Phase of HIV Life Cycle
  • Influenza Life Cycle
  • Regulation of cholesterol biosynthesis by SREBP (SREBF)
  • Export of Viral Ribonucleoproteins from Nucleus
  • HIV Life Cycle
  • Rev-mediated nuclear export of HIV RNA
  • NEP/NS2 Interacts with the Cellular Export Machinery
  • Flunisolide
  • Diflorasone
  • Alclometasone
  • Medrysone
  • Amcinonide
  • Fluorometholone
  • Megestrol
  • Beclometasone dipropionate
  • Betamethasone
  • Desoximetasone
  • Fluticasone Propionate
  • Fluocinolone Acetonide
  • Halobetasol Propionate
  • Triamcinolone
  • Prednisone
  • Flumethasone Pivalate
  • Fludrocortisone
  • Hydrocortisone
  • Mometasone
  • Hydrocortamate
  • Mifepristone
  • Clocortolone
  • Flurandrenolide
  • Prednisolone
  • Loteprednol
  • Rimexolone
  • Methylprednisolone
  • Clobetasol
  • Fluocinonide
  • Prednicarbate
  • Fluoxymesterone
  • Budesonide
  • Dexamethasone
  • Desonide
  • Cortisone acetate
  • Paramethasone
  • Ciclesonide
  • Hexane-1,6-Diol
  • Difluprednate
  • Fluticasone furoate
CSNK2A1 and CANX casein kinase 2, alpha 1 polypeptide calnexin
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • Diseases of glycosylation
  • Defective ALG14 causes congenital myasthenic syndrome (ALG14-CMS)
  • Defective MGAT2 causes MGAT2-CDG (CDG-2a)
  • Defective ALG1 causes ALG1-CDG (CDG-1k)
  • Antigen Presentation: Folding, assembly and peptide loading of class I MHC
  • Virus Assembly and Release
  • Defective MOGS causes MOGS-CDG (CDG-2b)
  • Influenza Life Cycle
  • Defective ALG9 causes ALG9-CDG (CDG-1l)
  • Defective MAN1B1 causes MRT15
  • MHC class II antigen presentation
  • Class I MHC mediated antigen processing & presentation
  • N-glycan trimming in the ER and Calnexin/Calreticulin cycle
  • Assembly of Viral Components at the Budding Site
  • Defective ALG11 causes ALG11-CDG (CDG-1p)
  • Defective ALG2 causes ALG2-CDG (CDG-1i)
  • Post-translational protein modification
  • Defective ALG3 causes ALG3-CDG (CDG-1d)
  • Defective DPAGT1 causes DPAGT1-CDG (CDG-1j) and CMSTA2
  • Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)
  • Influenza Infection
  • Defective RFT1 causes RFT1-CDG (CDG-1n)
  • Defective ALG6 causes ALG6-CDG (CDG-1c)
  • Asparagine N-linked glycosylation
  • Defective ALG8 causes ALG8-CDG (CDG-1h)
  • Defective MPDU1 causes MPDU1-CDG (CDG-1f)
  • Defective ALG12 causes ALG12-CDG (CDG-1g)
  • Diseases associated with N-glycosylation of proteins
  • Adaptive Immune System
  • Calnexin/calreticulin cycle
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid
  • Antihemophilic Factor
  • Tenecteplase
CSNK2A1 and RPLP0 casein kinase 2, alpha 1 polypeptide ribosomal protein, large, P0
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • Nonsense-Mediated Decay (NMD)
  • Translation
  • SRP-dependent cotranslational protein targeting to membrane
  • Eukaryotic Translation Termination
  • Peptide chain elongation
  • Influenza Infection
  • Viral mRNA Translation
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • Influenza Life Cycle
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
  • Influenza Viral RNA Transcription and Replication
  • GTP hydrolysis and joining of the 60S ribosomal subunit
  • Eukaryotic Translation Initiation
  • Formation of a pool of free 40S subunits
  • Eukaryotic Translation Elongation
  • Cap-dependent Translation Initiation
  • Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid
CSNK2A1 and RPLP1 casein kinase 2, alpha 1 polypeptide ribosomal protein, large, P1
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • Nonsense-Mediated Decay (NMD)
  • Translation
  • SRP-dependent cotranslational protein targeting to membrane
  • Eukaryotic Translation Termination
  • Peptide chain elongation
  • Influenza Infection
  • Viral mRNA Translation
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • Influenza Life Cycle
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
  • Influenza Viral RNA Transcription and Replication
  • GTP hydrolysis and joining of the 60S ribosomal subunit
  • Eukaryotic Translation Initiation
  • Formation of a pool of free 40S subunits
  • Eukaryotic Translation Elongation
  • Cap-dependent Translation Initiation
  • Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid
CSNK2A1 and RPS3 casein kinase 2, alpha 1 polypeptide ribosomal protein S3
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • Nonsense-Mediated Decay (NMD)
  • Translation initiation complex formation
  • Translation
  • SRP-dependent cotranslational protein targeting to membrane
  • Eukaryotic Translation Termination
  • Peptide chain elongation
  • Influenza Infection
  • Viral mRNA Translation
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • Influenza Life Cycle
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
  • Ribosomal scanning and start codon recognition
  • Formation of the ternary complex, and subsequently, the 43S complex
  • Influenza Viral RNA Transcription and Replication
  • GTP hydrolysis and joining of the 60S ribosomal subunit
  • Eukaryotic Translation Initiation
  • Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
  • Formation of a pool of free 40S subunits
  • Eukaryotic Translation Elongation
  • Cap-dependent Translation Initiation
  • Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid
CSNK2A1 and RPS18 casein kinase 2, alpha 1 polypeptide ribosomal protein S18
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • Nonsense-Mediated Decay (NMD)
  • Translation initiation complex formation
  • Translation
  • SRP-dependent cotranslational protein targeting to membrane
  • Eukaryotic Translation Termination
  • Peptide chain elongation
  • Influenza Infection
  • Viral mRNA Translation
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • Influenza Life Cycle
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
  • Ribosomal scanning and start codon recognition
  • Formation of the ternary complex, and subsequently, the 43S complex
  • Influenza Viral RNA Transcription and Replication
  • GTP hydrolysis and joining of the 60S ribosomal subunit
  • Eukaryotic Translation Initiation
  • Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
  • Formation of a pool of free 40S subunits
  • Eukaryotic Translation Elongation
  • Cap-dependent Translation Initiation
  • Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid
CSNK2A1 and GTF2F1 casein kinase 2, alpha 1 polypeptide general transcription factor IIF, polypeptide 1, 74kDa
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • RNA Polymerase II Promoter Escape
  • mRNA Splicing
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase II Transcription
  • Abortive elongation of HIV-1 transcript in the absence of Tat
  • HIV Infection
  • Formation of the Early Elongation Complex
  • Tat-mediated elongation of the HIV-1 transcript
  • Tat-mediated HIV elongation arrest and recovery
  • RNA Pol II CTD phosphorylation and interaction with CE
  • RNA Polymerase II Pre-transcription Events
  • Influenza Life Cycle
  • HIV elongation arrest and recovery
  • HIV Transcription Initiation
  • HIV Life Cycle
  • RNA Pol II CTD phosphorylation and interaction with CE
  • Influenza Viral RNA Transcription and Replication
  • RNA Polymerase II HIV Promoter Escape
  • HIV Transcription Elongation
  • Processing of Capped Intron-Containing Pre-mRNA
  • mRNA Capping
  • mRNA Splicing - Minor Pathway
  • mRNA Splicing - Major Pathway
  • Influenza Infection
  • Pausing and recovery of Tat-mediated HIV elongation
  • Late Phase of HIV Life Cycle
  • Formation of RNA Pol II elongation complex
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • Pausing and recovery of HIV elongation
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Formation of the HIV-1 Early Elongation Complex
  • Viral Messenger RNA Synthesis
  • RNA Polymerase II Transcription Initiation
  • Transcription of the HIV genome
  • RNA Polymerase II Transcription Elongation
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid
CSNK2A1 and POLR2A casein kinase 2, alpha 1 polypeptide polymerase (RNA) II (DNA directed) polypeptide A, 220kDa
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • RNA Polymerase II Promoter Escape
  • mRNA Splicing
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • PIWI-interacting RNA (piRNA) biogenesis
  • Nucleotide Excision Repair
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase II Transcription
  • Abortive elongation of HIV-1 transcript in the absence of Tat
  • HIV Infection
  • Regulatory RNA pathways
  • Formation of the Early Elongation Complex
  • Tat-mediated elongation of the HIV-1 transcript
  • Tat-mediated HIV elongation arrest and recovery
  • Formation of transcription-coupled NER (TC-NER) repair complex
  • RNA Pol II CTD phosphorylation and interaction with CE
  • RNA Polymerase II Pre-transcription Events
  • Dual incision reaction in TC-NER
  • Influenza Life Cycle
  • HIV elongation arrest and recovery
  • HIV Life Cycle
  • HIV Transcription Initiation
  • Influenza Viral RNA Transcription and Replication
  • RNA Pol II CTD phosphorylation and interaction with CE
  • Transcriptional regulation of pluripotent stem cells
  • RNA Polymerase II HIV Promoter Escape
  • HIV Transcription Elongation
  • POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
  • Transcriptional regulation by small RNAs
  • Processing of Capped Intron-Containing Pre-mRNA
  • mRNA Capping
  • mRNA Splicing - Minor Pathway
  • mRNA Splicing - Major Pathway
  • MicroRNA (miRNA) biogenesis
  • Influenza Infection
  • Pausing and recovery of Tat-mediated HIV elongation
  • Late Phase of HIV Life Cycle
  • Formation of RNA Pol II elongation complex
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • Pausing and recovery of HIV elongation
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Transcription-coupled NER (TC-NER)
  • Viral Messenger RNA Synthesis
  • Formation of the HIV-1 Early Elongation Complex
  • RNA Polymerase II Transcription Initiation
  • Transcription of the HIV genome
  • RNA Polymerase II Transcription Elongation
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid
CSNK2A1 and RPL5 casein kinase 2, alpha 1 polypeptide ribosomal protein L5
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • Nonsense-Mediated Decay (NMD)
  • Translation
  • SRP-dependent cotranslational protein targeting to membrane
  • Eukaryotic Translation Termination
  • Peptide chain elongation
  • Influenza Infection
  • Viral mRNA Translation
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • Influenza Life Cycle
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
  • Influenza Viral RNA Transcription and Replication
  • GTP hydrolysis and joining of the 60S ribosomal subunit
  • Eukaryotic Translation Initiation
  • Formation of a pool of free 40S subunits
  • Eukaryotic Translation Elongation
  • Cap-dependent Translation Initiation
  • Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid
CSNK2A1 and RPL6 casein kinase 2, alpha 1 polypeptide ribosomal protein L6
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • Nonsense-Mediated Decay (NMD)
  • Translation
  • SRP-dependent cotranslational protein targeting to membrane
  • Eukaryotic Translation Termination
  • Peptide chain elongation
  • Influenza Infection
  • Viral mRNA Translation
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • Influenza Life Cycle
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
  • Influenza Viral RNA Transcription and Replication
  • GTP hydrolysis and joining of the 60S ribosomal subunit
  • Eukaryotic Translation Initiation
  • Formation of a pool of free 40S subunits
  • Eukaryotic Translation Elongation
  • Cap-dependent Translation Initiation
  • Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid
CSNK2A1 and RPL13 casein kinase 2, alpha 1 polypeptide ribosomal protein L13
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • Nonsense-Mediated Decay (NMD)
  • Translation
  • SRP-dependent cotranslational protein targeting to membrane
  • Eukaryotic Translation Termination
  • Peptide chain elongation
  • Influenza Infection
  • Viral mRNA Translation
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • Influenza Life Cycle
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
  • Influenza Viral RNA Transcription and Replication
  • GTP hydrolysis and joining of the 60S ribosomal subunit
  • Eukaryotic Translation Initiation
  • Formation of a pool of free 40S subunits
  • Eukaryotic Translation Elongation
  • Cap-dependent Translation Initiation
  • Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid
TOP2A and XPO1 topoisomerase (DNA) II alpha 170kDa exportin 1
  • G0 and Early G1
  • Mitotic G1-G1/S phases
  • Cell Cycle, Mitotic
  • Loss of Function of TGFBR2 in Cancer
  • Downregulation of TGF-beta receptor signaling
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Signaling by Wnt
  • TGF-beta receptor signaling activates SMADs
  • Influenza Life Cycle
  • Export of Viral Ribonucleoproteins from Nucleus
  • RNF mutants show enhanced WNT signaling and proliferation
  • Regulation of mRNA stability by proteins that bind AU-rich elements
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Host Interactions of HIV factors
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Influenza Infection
  • Late Phase of HIV Life Cycle
  • Resolution of Sister Chromatid Cohesion
  • Mitotic G2-G2/M phases
  • Mitotic Metaphase and Anaphase
  • Mitotic Prometaphase
  • Separation of Sister Chromatids
  • HIV Infection
  • Rev-mediated nuclear export of HIV RNA
  • G2/M Transition
  • Mitotic Anaphase
  • TGFBR1 LBD Mutants in Cancer
  • HuR stabilizes mRNA
  • deactivation of the beta-catenin transactivating complex
  • M Phase
  • HIV Life Cycle
  • Rev-mediated nuclear export of HIV RNA
  • Cyclin A/B1 associated events during G2/M transition
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • NEP/NS2 Interacts with the Cellular Export Machinery
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Interactions of Rev with host cellular proteins
  • Cell Cycle, Mitotic
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • TCF dependent signaling in response to WNT
  • Signaling by WNT in cancer
  • SMAD4 MH2 Domain Mutants in Cancer
  • Moxifloxacin
  • Amsacrine
  • Dexrazoxane
  • Valrubicin
  • Teniposide
  • Epirubicin
  • Enoxacin
  • Pefloxacin
  • Ciprofloxacin
  • Trovafloxacin
  • Daunorubicin
  • Etoposide
  • Lomefloxacin
  • Doxorubicin
  • Norfloxacin
  • Levofloxacin
  • Ofloxacin
  • Idarubicin
  • Podofilox
  • Mitoxantrone
  • Sparfloxacin
  • Genistein
  • Fleroxacin
  • Lucanthone
GSK3B and RPLP1 glycogen synthase kinase 3 beta ribosomal protein, large, P1
  • Signaling by the B Cell Receptor (BCR)
  • Hedgehog 'off' state
  • Signaling by FGFR in disease
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Degradation of beta-catenin by the destruction complex
  • PI3K/AKT activation
  • PI-3K cascade
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • deletions in the AMER1 gene destabilize the destruction complex
  • AMER1 mutants destabilize the destruction complex
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • CRMPs in Sema3A signaling
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • APC truncation mutants have impaired AXIN binding
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • Signalling by NGF
  • Semaphorin interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Regulation of HSF1-mediated heat shock response
  • Cellular response to heat stress
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • TCF dependent signaling in response to WNT
  • Signaling by Hedgehog
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Nonsense-Mediated Decay (NMD)
  • Translation
  • SRP-dependent cotranslational protein targeting to membrane
  • Eukaryotic Translation Termination
  • Peptide chain elongation
  • Influenza Infection
  • Viral mRNA Translation
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • Influenza Life Cycle
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
  • Influenza Viral RNA Transcription and Replication
  • GTP hydrolysis and joining of the 60S ribosomal subunit
  • Eukaryotic Translation Initiation
  • Formation of a pool of free 40S subunits
  • Eukaryotic Translation Elongation
  • Cap-dependent Translation Initiation
  • Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
  • Lithium
  • 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
  • I-5
  • N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea
  • Staurosporine
  • Indirubin-3\'-Monoxime
  • Adenosine-5\'-Diphosphate
  • (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime
  • Alsterpaullone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
  • 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
  • (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one
  • N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
  • 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
  • ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
  • (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
GSK3B and RPS2 glycogen synthase kinase 3 beta ribosomal protein S2
  • Signaling by the B Cell Receptor (BCR)
  • Hedgehog 'off' state
  • Signaling by FGFR in disease
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Degradation of beta-catenin by the destruction complex
  • PI3K/AKT activation
  • PI-3K cascade
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • deletions in the AMER1 gene destabilize the destruction complex
  • AMER1 mutants destabilize the destruction complex
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • CRMPs in Sema3A signaling
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • APC truncation mutants have impaired AXIN binding
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • Signalling by NGF
  • Semaphorin interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Regulation of HSF1-mediated heat shock response
  • Cellular response to heat stress
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • TCF dependent signaling in response to WNT
  • Signaling by Hedgehog
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Nonsense-Mediated Decay (NMD)
  • Translation initiation complex formation
  • Translation
  • SRP-dependent cotranslational protein targeting to membrane
  • Eukaryotic Translation Termination
  • Peptide chain elongation
  • Influenza Infection
  • Viral mRNA Translation
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • Influenza Life Cycle
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
  • Ribosomal scanning and start codon recognition
  • Formation of the ternary complex, and subsequently, the 43S complex
  • Influenza Viral RNA Transcription and Replication
  • GTP hydrolysis and joining of the 60S ribosomal subunit
  • Eukaryotic Translation Initiation
  • Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
  • Formation of a pool of free 40S subunits
  • Eukaryotic Translation Elongation
  • Cap-dependent Translation Initiation
  • Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
  • Lithium
  • 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
  • I-5
  • N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea
  • Staurosporine
  • Indirubin-3\'-Monoxime
  • Adenosine-5\'-Diphosphate
  • (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime
  • Alsterpaullone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
  • 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
  • (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one
  • N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
  • 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
  • ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
  • (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
HTR3A and CANX 5-hydroxytryptamine (serotonin) receptor 3A, ionotropic calnexin
  • Ion channel transport
  • Ligand-gated ion channel transport
  • Diseases of glycosylation
  • Defective ALG14 causes congenital myasthenic syndrome (ALG14-CMS)
  • Defective MGAT2 causes MGAT2-CDG (CDG-2a)
  • Defective ALG1 causes ALG1-CDG (CDG-1k)
  • Antigen Presentation: Folding, assembly and peptide loading of class I MHC
  • Virus Assembly and Release
  • Defective MOGS causes MOGS-CDG (CDG-2b)
  • Influenza Life Cycle
  • Defective ALG9 causes ALG9-CDG (CDG-1l)
  • Defective MAN1B1 causes MRT15
  • MHC class II antigen presentation
  • Class I MHC mediated antigen processing & presentation
  • N-glycan trimming in the ER and Calnexin/Calreticulin cycle
  • Assembly of Viral Components at the Budding Site
  • Defective ALG11 causes ALG11-CDG (CDG-1p)
  • Defective ALG2 causes ALG2-CDG (CDG-1i)
  • Post-translational protein modification
  • Defective ALG3 causes ALG3-CDG (CDG-1d)
  • Defective DPAGT1 causes DPAGT1-CDG (CDG-1j) and CMSTA2
  • Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)
  • Influenza Infection
  • Defective RFT1 causes RFT1-CDG (CDG-1n)
  • Defective ALG6 causes ALG6-CDG (CDG-1c)
  • Asparagine N-linked glycosylation
  • Defective ALG8 causes ALG8-CDG (CDG-1h)
  • Defective MPDU1 causes MPDU1-CDG (CDG-1f)
  • Defective ALG12 causes ALG12-CDG (CDG-1g)
  • Diseases associated with N-glycosylation of proteins
  • Adaptive Immune System
  • Calnexin/calreticulin cycle
  • Ziprasidone
  • Olanzapine
  • Clozapine
  • Mirtazapine
  • Palonosetron
  • Cisapride
  • Procaine
  • Rocuronium
  • Dolasetron
  • Granisetron
  • Ondansetron
  • Alosetron
  • Memantine
  • Chloroprocaine
  • Tubocurarine
  • Quetiapine
  • Aripiprazole
  • Tapentadol
  • Antihemophilic Factor
  • Tenecteplase
METAP2 and EIF2AK2 methionyl aminopeptidase 2 eukaryotic translation initiation factor 2-alpha kinase 2
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Visual phototransduction
  • The phototransduction cascade
  • Diseases associated with visual transduction
  • ISG15 antiviral mechanism
  • Interferon Signaling
  • Inhibition of PKR
  • Cytokine Signaling in Immune system
  • Host Interactions with Influenza Factors
  • Influenza Infection
  • NS1 Mediated Effects on Host Pathways
  • Antiviral mechanism by IFN-stimulated genes
  • L-Methionine
  • 3,5,6,8-Tetramethyl-N-Methyl Phenanthrolinium
  • Fumagillin
  • D-Methionine
  • N\'-(2s,3r)-3-Amino-4-Cyclohexyl-2-Hydroxy-Butano-N-(4-Methylphenyl)Hydrazide
  • (E)-(2r,3r,4s,5r)-3,4,5-Trihydroxy-2-Methoxy-8,8-Dimethyl-Non-6-Enoic Acid ((3s,6r)-6-Hydroxy-2-Oxo-Azepan-3-Yl)-Amide
  • 2-Methyl-2-Propanol
  • (2s,3r)-3-Amino-2-Hydroxy-5-(Ethylsulfanyl)Pentanoyl-((S)-(-)-(1-Naphthyl)Ethyl)Amide
  • Ovalicin
  • 5-BROMO-2-{[(4-CHLOROPHENYL)SULFONYL]AMINO}BENZOIC ACID
  • 5-METHYL-2-[(PHENYLSULFONYL)AMINO]BENZOIC ACID
  • 2-[(PHENYLSULFONYL)AMINO]-5,6,7,8-TETRAHYDRONAPHTHALENE-1-CARBOXYLIC ACID
  • 2-[({2-[(1Z)-3-(DIMETHYLAMINO)PROP-1-ENYL]-4-FLUOROPHENYL}SULFONYL)AMINO]-5,6,7,8-TETRAHYDRONAPHTHALENE-1-CARBOXYLIC ACID
  • N\'-((2S,3R)-3-AMINO-2-HYDROXY-5-(ISOPROPYLSULFANYL)PENTANOYL)-N-3-CHLOROBENZOYL HYDRAZIDE
  • 3-ETHYL-6-{[(4-FLUOROPHENYL)SULFONYL]AMINO}-2-METHYLBENZOIC ACID
  • (CHLOROACETYL)CARBAMIC ACID (3R,4S,5S,5R)-5-METHOXY-4-[(2R,3R)-2-METHYL-3-(3-METHYL-2-BUTENYL)OXIRANYL]-1-OXASPIRO[2.5]OCT-6-YL ESTER

Page 8 out of 89 pages